Bispecific antibodies targeting mutant RAS neoantigens
Diabodies see the unseeable RAS oncogene mutations are common in various cancers, controlling their growth and survival. Targeting mutant RAS proteins with antibodies has been unsuccessful due to low surface expression, even when targeting mutant RAS peptides presented via HLA on the surface of cancer cells. Douglass et al. used phage display to generate single-chain variable fragments (scFvs) specific for mutant RAS peptide-HLA complexes. The authors tested various bispecific, T cell–engagi...
Rock Springs United States Astra Zeneca Medimmune Amplimmune Ultramer Oligos Bristol Myers Squibb Johns Hopkins University
Source: sciencemag.org